Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aveo Pharmaceuticals Inc (NASDAQ:AVEO)

0.9519
Delayed Data
As of Jun 24
 -0.0282 / -2.88%
Today’s Change
0.82
Today|||52-Week Range
2.59
-24.45%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$55.4M

Company Description

AVEO Pharmaceuticals, Inc. operates as a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. Its proprietary human response platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. The company's product candidates include AV-203, ficlatuzumab, tivozanib and AV-380. AVEO Pharmaceuticals was founded by Ronald A. DePinho, Lynda Chin and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Contact Information

AVEO Pharmaceuticals, Inc.
One Broadway
Cambridge Massachusetts 02142
P:(617) 588-1960
Investor Relations:

Employees

Shareholders

Mutual fund holders5.64%
Individual stakeholders30.56%
Other institutional17.00%

Top Executives

Michael P. BaileyPresident, Chief Executive Officer & Director
Keith S. EhrlichChief Financial Officer
Emile FarhanVice President-Technical Operations
Michael N. NeedleChief Medical Officer
Karuna RubinSecretary, Head-Legal Affairs & Compliance